Actively Recruiting
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-06
60
Participants Needed
1
Research Sites
207 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, single-center, clinical study to evaluate the efficacy and safety of a fully immunotherapy-based strategy guided by MRD-driven dynamic risk stratification in transplant-ineligible patients with newly diagnosed multiple myeloma.
CONDITIONS
Official Title
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years
- Newly diagnosed multiple myeloma according to IMWG diagnostic criteria
- Measurable disease defined by serum or urine M-protein levels or abnormal serum Ig free-light chain levels
- Ineligible for high-dose chemotherapy with stem cell transplantation due to age 65 or older, investigator assessment, ECOG status 3-4, stem cell mobilization failure, or patient decision
- Tumor cells positive for BCMA and GPRC5D
- Serum total bilirubin less than 2 times upper limit of normal, AST and ALT less than 3 times upper limit of normal, creatinine clearance at least 30 mL/min
- Ability and willingness to provide written informed consent
You will not qualify if you...
- Active amyloidosis
- Central nervous system involvement
- Prior BCMA-targeted therapy or CAR-T therapy
- Active hepatitis B or hepatitis C infection
- Known HIV infection
- Life expectancy less than 6 months
- Pregnant or breastfeeding women
- Uncontrolled dysfunction of heart, lung, brain, or other important organs
- Any other conditions judged as ineligible by the principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Actively Recruiting
Research Team
G
Gang An, PhD&MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here